CryoPort (NASDAQ:CYRX) Shares Pass Above 200 Day Moving Average - What's Next?

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.65 and traded as high as $7.72. CryoPort shares last traded at $7.50, with a volume of 328,354 shares.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on CYRX shares. UBS Group increased their target price on shares of CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Guggenheim reissued a "buy" rating and issued a $10.00 price target on shares of CryoPort in a report on Wednesday, April 16th. Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of CryoPort in a research report on Thursday, May 8th. Morgan Stanley reduced their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, BTIG Research dropped their target price on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.88.

CryoPort Stock Down 0.3%

The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The company has a market cap of $372.54 million, a price-to-earnings ratio of -3.18 and a beta of 1.89. The stock has a fifty day moving average price of $6.83 and a two-hundred day moving average price of $6.65.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. As a group, sell-side analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling

In other news, insider Edward J. Zecchini sold 51,500 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total transaction of $352,260.00. Following the completion of the transaction, the insider owned 90,411 shares in the company, valued at approximately $618,411.24. This represents a 36.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ramkumar Mandalam sold 13,321 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.01, for a total value of $93,380.21. Following the completion of the sale, the director directly owned 73,056 shares in the company, valued at approximately $512,122.56. The trade was a 15.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 449,719 shares of company stock valued at $3,042,327. 10.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently modified their holdings of the stock. Avanza Fonder AB grew its position in CryoPort by 31.4% during the second quarter. Avanza Fonder AB now owns 10,882 shares of the company's stock valued at $81,000 after buying an additional 2,601 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of CryoPort by 7.3% in the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company's stock worth $8,135,000 after buying an additional 73,949 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in CryoPort during the 2nd quarter valued at approximately $123,000. Rhumbline Advisers raised its stake in CryoPort by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after purchasing an additional 15,036 shares during the period. Finally, Acadian Asset Management LLC raised its stake in CryoPort by 106.4% during the 1st quarter. Acadian Asset Management LLC now owns 479,695 shares of the company's stock valued at $2,911,000 after purchasing an additional 247,288 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.